StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences non-GAAP other income (expense) adjustments (equity securities fair value, $M) ($M)

Form 8-K GAAP to Non-GAAP Reconciliation

Latest, FY2025
-451
Period ended Dec 31, 2025
Change on a year earlier
-264.6%
274 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP other income (expense) adjustments (equity securities fair value, $M) ($M)Year on yearSource
FY2025Dec 31, 2025-451-264.6%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
FY2024Dec 31, 2024274+64.1%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
FY2023Dec 31, 2023167-74.6%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
FY2022Dec 31, 2022657+7.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
FY2021Dec 31, 2021610-63.4%Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
FY2020Dec 31, 20201,667-234.3%Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗
FY2019Dec 31, 2019-1,241+979.1%Form 8-K (exhibit991earningspressrel.htm, filed 2021-02-04) ↗
FY2018Dec 31, 2018-115–Form 8-K (exhibit991earningspres.htm, filed 2020-02-04) ↗

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP other income (expense) adjustments (equity securities fair value, $M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng_adj_other_inc

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.